Company intelligence / Profile preview

Numan

London, United Kingdomnuman.com ↗

Ownership: Private
Employees: ~357
Development stage: Commercial

Overview

Numan operates a commercial-stage digital health platform focused on providing accessible care for stigmatized conditions such as obesity and testosterone deficiency. The company has rapidly expanded its offering to include both men’s and women’s health with a strong focus on GLP‑1-based weight management. It reports treating over >100,000 patients with significant year-on-year growth (~200% YoY in early months of 2025). Clinical results are not published in the traditional sense but patient acquisition and retention metrics indicate high engagement.

Therapeutic areas: EndocrinologyDermatologyMen's Health
Modalities: Small moleculeSupplementDevice
Industry: Non-Academic Healthcare

Drug pipeline

1 asset

sildenafil

Commercial

Indications: Erectile dysfunction

Partnerships

Marius Pharmaceuticals

Beyond the preview

Go deeper on Numan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Numan.

Explore the full profile